Mesothelioma Cancer Centers
City of Hope
Doctors Affiliated with this Treatment Facility
City of Hope was founded in 1913 as a free tuberculosis hospital by the Jewish Consumptive Relief Association. Originally called the Los Angeles Sanatorium, the hospital attracted the patronage of Hollywood celebrities and philanthropists. In 1949, the hospital officially changed its name to City of Hope, reflecting a new goal of creating a full-service center for research, treatment and education, with a focus on compassionate patient care.
From its original 40 acres, the campus has expanded over the years to more than 100 acres. A research institute was established in 1952, and Hope Village, which allowed patients and their loved ones to stay together near the hospital during treatment. As City of Hope’s physical presence grew, so did its research efforts, with Hope physicians and scientists pioneering studies in neurogenetics, recombinant DNA and tumor development. In 1983, the Beckman Research Institute was founded with an initial grant of $10 million from the Arnold and Mabel Beckman Foundation. In the late 1990’s, City of Hope was awarded the National Cancer Institute’s Comprehensive Cancer Center designation, identifying it as a top cancer center for research and patient care.
City of Hope offers cancer treatment and care to malignant mesothelioma patients with a specific focus on pleural mesothelioma. Their multidisciplinary team includes experts in treating aggressive and advanced thoracic cancers.
The mesothelioma experts at the City of Hope cancer center practice standard treatment techniques, such as surgery, chemotherapy and radiation therapy, but also focus on emerging treatments through clinical trials.
For mesothelioma patients undergoing surgery, their experts prefer minimally invasive options that will cause the least amount of harm on the body with the fastest recovery time. City of Hope stands out from other cancer centers in their use of newer radiation therapies, such as Helical TomoTherapy, four-dimensional computed tomography, intensity-modulated radiation therapy and stereotactic body radiation.
In addition to offering support for patients and their families during their treatment journey, City of Hope offers strong survivorship programs for those that have successfully completed treatment.
- Aggressive and late-stage lung cancers
- Minimally invasive thoracic surgeries
- Pleural mesothelioma
- National Cancer Institute Designated Comprehensive Cancer Center
- National Comprehensive Cancer Network
- U.S. News Best Hospitals for Cancer designation
Mesothelioma Clinical Trials at City of Hope
The following clinical trials are in progress or actively recruiting participants at City of Hope:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 18, 2019 Status: Recruiting
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelin Positive; Pleural Malignant Mesothelioma Last Updated: July 17, 2019 Status: Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Solid Tumors; Malignant Pleural Mesothelioma; Gastric Adenocarcinoma; Colorectal Adenocarcinoma; Sarcoma Last Updated: July 17, 2019 Status: Recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7 Last Updated: July 4, 2019 Status: Recruiting
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm Last Updated: June 10, 2019 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
City of Hope. Mesothelioma.